Despite the fact that 9-ING-41 can be active on mutant as well as wild-type KRAS cancer cells, several reports suggest that GSK-3 can be specifically important for the malignant cells harboring mutations in the KRAS oncogene, and thus, inhibition of GSK-3 can be especially beneficial for the treatment of such cancers. The gene discussed is KRAS; the disease is cancer.